厄罗替尼联合贝伐珠单抗在非小细胞肺癌中的运用分析  

Analysis and application of Erlotinib combined with Bevacizumab in the treatment of non-small cell lung cancer

作　　者：秦东强 王英 

机构地区：[1]新疆独山子人民医院,新疆克拉玛依833600

出　　处：《转化医学电子杂志》2015年第8期82-83,共2页E-Journal of Translational Medicine

摘　　要：目的:分析厄罗替尼联合贝伐珠单抗应用于非小细胞肺癌中的临床效果.方法:选取2013-01/2015-03来我院治疗的非小细胞肺癌患者26例作为研究对象,所有患者口服厄罗替尼150 mg/d,1次/d,静脉滴注贝伐珠单抗15 mg/kg,1次/d,治疗3周(1个疗程)后,直至疾病进展,观察分析其近期疗效及不良反应.结果:本组患者CR、PR、SD、PD分别为8例、8例、6例、4例,有效率为61.54%;中位生存时间为(57.54±2.45)周;本组皮疹10例、腹泻8例、出血4例,均无1例患者因毒副反应而停止用药.结论:非小细胞肺癌采取厄罗替尼联合贝伐珠单抗治疗的临床效果显著,且毒副反应少,值得临床推广使用.AIM: To analyze the clinical effects of Erlotinib combined with Bevacizumab in the application of non?small cell lung cancer ( NSCLC ) . METHODS: A total of 26 cases with non?small cell lung cancer admitted into our hospital from January 2013 to March 2015 were selected as the objects of research. All patients were treated with oral Erlotinib ( 150 mg/d, once a day); intravenous infusion of Bevacizumab ( 15 mg/kg, once a day); A course of treatment was 3 weeks. The treatment will continue until there is an better progression in the treatment of the non?small cell lung cancer, and observing and analyzing the efficacy and adverse reactions. RESULTS:There were 8 cases of CR, 8 cases of PR, 7 cases of SD and 4 cases of PD in the group and the efficiency was 61. 54%; the median survival time was (57.54 ±2.45) weeks. There were 10 cases of rash, 8 cases of diarrhea, 4 cases of bleeding without the patient who have stoped the medication due to the adverse toxicity reactions. CONCLU?SION: The application of Erlotinib combined with Bevacizumab in the treatment of non?small cell lung cancer has a significant clinical effect with less adverse toxicity reactions, which is worthy of clinical promotion.

关 键 词：非小细胞肺癌 厄罗替尼 贝伐珠单抗 毒副反应 

分 类 号：R734[医药卫生—肿瘤]